Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis-Reference-Cited by-同舟云学术

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

Published:2006-09 Issue:9 Volume:7 Page:741-746
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Johnson Kent R,Ringland Clare,Stokes Barrie J,Anthony Danielle M,Freemantle Nick,Irs Alar,Hill Suzanne R,Ward Robyn L

Publisher

Elsevier BV

Subject

Oncology

Reference16 articles.

1. Policy developments in regulatory approval;Temple;Stat Med,2002

2. Reporting results of cancer treatment;Miller;Cancer,1981

3. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria;Green;Invest New Drugs,1992

4. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

5. Comparison of RECIST and WHO response criteria in metastatic colorectal carcinoma;Choi;J Clin Oncol,2005

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer;Clinical Cancer Research;2024-02-20

2. Clinical Outcomes After Personalized Dosimetry for⁹⁰Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape;Journal of Nuclear Medicine;2024-01-11

3. Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework;Therapeutic Advances in Medical Oncology;2024-01

4. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer;Frontiers in Oncology;2023-05-02

5. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer;Nature Medicine;2023-03